These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7590519)

  • 61. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
    Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
    Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
    Kebabian JW; Britton DR; DeNinno MP; Perner R; Smith L; Jenner P; Schoenleber R; Williams M
    Eur J Pharmacol; 1992 Dec; 229(2-3):203-9. PubMed ID: 1362704
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset.
    Gibb WR; Lees AJ; Jenner P; Marsden CD
    Neurosci Lett; 1986 Mar; 65(1):79-83. PubMed ID: 3486388
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
    Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
    Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease.
    Kunikowska G; Jenner P
    Brain Res; 2003 Apr; 968(2):206-18. PubMed ID: 12663090
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of ropinirole on motor behavior in MPTP-treated common marmosets.
    Fukuzaki K; Kamenosono T; Kitazumi K; Nagata R
    Pharmacol Biochem Behav; 2000 Sep; 67(1):121-9. PubMed ID: 11113491
    [TBL] [Abstract][Full Text] [Related]  

  • 70. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
    Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD
    Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
    Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Voxel-based morphometry of the marmoset brain: In vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson's disease model.
    Hikishima K; Ando K; Komaki Y; Kawai K; Yano R; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H
    Neuroscience; 2015 Aug; 300():585-92. PubMed ID: 26012491
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
    van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH
    Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Metabolism of adenosine increase in the striatum in common marmoset parkinsonism induced by MPTP.
    Nomoto M; Shimizu T; Iwata S; Kaseda S; Fukuda T
    Adv Neurol; 1999; 80():125-8. PubMed ID: 10410711
    [No Abstract]   [Full Text] [Related]  

  • 77. Individual and Familial Susceptibility to MPTP in a Common Marmoset Model for Parkinson's Disease.
    Franke SK; van Kesteren RE; Hofman S; Wubben JA; Smit AB; Philippens IH
    Neurodegener Dis; 2016; 16(5-6):293-303. PubMed ID: 26999593
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset.
    Pérez-Otaño I; Herrero MT; Oset C; De Ceballos ML; Luquin MR; Obeso JA; Del Río J
    Brain Res; 1991 Dec; 567(1):127-32. PubMed ID: 1815820
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.
    Temlett JA; Chong PN; Oertel WH; Jenner P; Marsden CD
    Eur J Pharmacol; 1988 Nov; 156(2):197-206. PubMed ID: 2977118
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW
    Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.